• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nivolumab-induced asthma in a patient with non-small-cell lung cancer.

作者信息

Maeno K, Fukuda S, Oguri T, Niimi A

机构信息

Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

Ann Oncol. 2017 Nov 1;28(11):2891. doi: 10.1093/annonc/mdx455.

DOI:10.1093/annonc/mdx455
PMID:28945837
Abstract
摘要

相似文献

1
Nivolumab-induced asthma in a patient with non-small-cell lung cancer.纳武单抗诱发非小细胞肺癌患者哮喘发作
Ann Oncol. 2017 Nov 1;28(11):2891. doi: 10.1093/annonc/mdx455.
2
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.非小细胞肺癌患者接受纳武单抗治疗期间出现的与抗程序性死亡蛋白1相关的冷球蛋白血症。
Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.
3
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.纳武利尤单抗治疗晚期转移性非小细胞肺癌的日本患者：疗效和安全性临床试验证据的综述。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.
4
Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?免疫检查点抑制是否属于Ⅲ期非小细胞肺癌标准治疗的一部分？
Cancer. 2018 Jul 15;124(14):2878-2880. doi: 10.1002/cncr.31557. Epub 2018 Jun 15.
5
HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors.接受PD-1抑制剂治疗的HTLV-1血清阳性肺癌患者。
Cancer Sci. 2020 Sep;111(9):3395-3396. doi: 10.1111/cas.14536. Epub 2020 Jul 18.
6
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.PD-1/PD-L1 轴免疫检查点抑制剂在非小细胞肺癌中的应用：新型治疗模式中的前景、争议和不确定性。
Scand J Clin Lab Invest. 2020 Sep;80(5):360-369. doi: 10.1080/00365513.2020.1742369. Epub 2020 Apr 2.
7
New onset of psoriasis during nivolumab treatment for lung cancer.在使用纳武单抗治疗肺癌期间新发银屑病。
J Dermatol. 2018 Mar;45(3):e55-e56. doi: 10.1111/1346-8138.14167. Epub 2017 Dec 4.
8
Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.纳武单抗诱导的转移性非小细胞肺癌患者免疫性血小板减少症
Oncol Res Treat. 2017;40(10):621-622. doi: 10.1159/000477968. Epub 2017 Sep 19.
9
Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.三例与用于治疗非小细胞肺癌的抗程序性细胞死亡和程序性细胞死亡配体药物相关的免疫性胆管炎。
Eur J Cancer. 2019 Jul;115:107-110. doi: 10.1016/j.ejca.2019.04.022. Epub 2019 May 24.
10
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.分析接受抗 PD-1 治疗的晚期非小细胞肺癌患者的预先存在的抗体。
JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860.

引用本文的文献

1
Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review.免疫检查点抑制剂引发的慢性嗜酸性粒细胞性肺炎的成功管理：一例报告及文献综述
Front Immunol. 2025 Jul 22;16:1615531. doi: 10.3389/fimmu.2025.1615531. eCollection 2025.
2
Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.免疫检查点抑制剂治疗后2型辅助性T细胞炎症性疾病的综述
Biomedicines. 2024 Aug 19;12(8):1886. doi: 10.3390/biomedicines12081886.
3
Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report.
帕博利珠单抗诱发子宫内膜癌患者哮喘加重伴嗜酸性粒细胞增多和白细胞介素-5升高：一例报告
Respir Med Case Rep. 2024 Apr 30;49:102035. doi: 10.1016/j.rmcr.2024.102035. eCollection 2024.
4
The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.阿替利珠单抗联合安罗替尼治疗广泛期小细胞肺癌患者后出现哮喘：1 例病例报告。
Front Immunol. 2024 Feb 29;15:1333850. doi: 10.3389/fimmu.2024.1333850. eCollection 2024.
5
Immune checkpoint inhibitor-induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma.免疫检查点抑制剂诱发腺癌患者出现哮喘与慢性阻塞性肺疾病重叠综合征
Respirol Case Rep. 2023 Sep 19;11(10):e01222. doi: 10.1002/rcr2.1222. eCollection 2023 Oct.
6
Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review.与免疫检查点抑制剂给药相关的机会性感染和免疫相关不良事件：一项叙述性综述。
Pharmaceuticals (Basel). 2023 Aug 9;16(8):1119. doi: 10.3390/ph16081119.
7
Therapeutic properties of Helicobacter pylori-derived vacuolating cytotoxin A in an animal model of chronic allergic airway disease.空泡细胞毒素 A 治疗慢性变应性气道疾病动物模型的研究
Respir Res. 2023 Jul 6;24(1):178. doi: 10.1186/s12931-023-02484-5.
8
Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.免疫检查点抑制剂治疗后的结节病和气道疾病：病例研究及文献综述
J Immunother Precis Oncol. 2023 Mar 21;6(2):111-116. doi: 10.36401/JIPO-22-30. eCollection 2023 May.
9
Immune checkpoint molecules in prevention and development of asthma.免疫检查点分子在哮喘的预防和发展中的作用。
Front Immunol. 2023 Feb 14;14:1070779. doi: 10.3389/fimmu.2023.1070779. eCollection 2023.
10
Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.免疫检查点抑制剂引起的呼吸系统毒性：一项基于美国食品药品监督管理局不良事件报告系统数据库的真实世界研究。
Front Oncol. 2022 Aug 19;12:941079. doi: 10.3389/fonc.2022.941079. eCollection 2022.